Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Jaguar Health's family company Napo Pharmaceuticals announced acceptance of an abstract with preliminary open-label crofelemer data in adult short bowel syndrome with intestinal failure (SBS-IF) for presentation at ACG 2026, held October 9-14 in Nashville. A separate multicenter, randomized double-blind placebo-controlled Phase 2 trial in adult Type 1 SBS patients without colon-in-continuity is ongoing, with results expected early in the second half of 2027. Prior data in pediatric intestinal failure patients showed substantial reductions in weekly parenteral support needs with no significant clinical or laboratory abnormalities.
Key figures
- Drug Name
- crofelemer (powder for oral solution)
- Phase Of Trial
- Phase 2
- Mvid nda filing
- mid-2027
- Phase2 sbs data timing
- early second half of 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.